Houston, Texas, October 5, 2026
PackGene Biotech has demonstrated expanded capabilities in scalable AAV manufacturing through its work within the Dyno Frontiers Network, supporting gene therapy developers using next-generation capsids engineered by Dyno Therapeutics. The company announced the delivery of multiple client manufacturing projects at the 10-liter production scale, generating high-quality adeno-associated virus (AAV) material for large-animal preclinical studies. The latest results highlight PackGene’s ability to manufacture across multiple engineered capsids and transgene payloads while maintaining consistent product quality. Through its proprietary manufacturing platform, the company has evaluated production across five Dyno capsids, providing additional evidence that its process can support emerging gene therapy programs from early development toward more advanced preclinical and clinical stages.
PackGene Demonstrates Manufacturing Across Five Dyno Capsids
Earlier in 2026, PackGene joined the Dyno Frontiers Network, an ecosystem established by Dyno Therapeutics to support gene therapy developers working with advanced capsid technologies. Since joining the network, PackGene has evaluated its manufacturing platform across five Dyno capsids and two different transgene payloads, demonstrating the flexibility of its established production process. Engineered AAV capsids are being developed to improve characteristics such as tissue targeting and delivery, but successful translation of these technologies also depends on the ability to manufacture them consistently at useful scales. PackGene’s work addresses this manufacturing requirement by applying its established AAV production and process development capabilities to multiple capsid designs. The company’s results indicate that its platform can accommodate different AAV architectures while producing material suitable for demanding preclinical development programs.
10-Liter Production Supports Large-Animal Studies
PackGene has delivered three client AAV manufacturing projects at 10-liter scale across two Dyno capsids, supporting large-animal model studies for gene therapy development. The manufacturing work uses PackGene’s proprietary π-Alpha 293 AAV Platform, which incorporates suspension cell culture together with column-based downstream processing. According to the company, the platform generated favorable product quality characteristics, including full/empty capsid ratios above 80% in final products. Full capsids contain the intended genetic payload, while empty capsids lack the therapeutic genetic material and can affect product quality and manufacturing efficiency. Achieving a favorable full-to-empty ratio is therefore an important consideration in AAV vector manufacturing. The successful production of material at 10-liter scale also represents an important step for programs progressing beyond laboratory-scale research toward larger preclinical studies, where substantially greater quantities of consistent AAV material may be required.
Advertisement
Supporting the Next Generation of Gene Therapy Programs
PackGene said the manufacturing results demonstrate the importance of connecting innovative AAV capsid design with reliable manufacturing processes. As gene therapy developers increasingly explore engineered capsids intended to improve delivery to specific tissues, manufacturing partners must be able to translate these designs into reproducible production processes. PackGene provides AAV manufacturing and process development support across development stages, ranging from research-grade and preclinical material through GMP production. The company’s continued work with the Dyno Frontiers Network is intended to support developers using engineered capsids as their programs advance. Additional studies involving other Dyno capsids are ongoing, with further data expected later in 2026. By demonstrating production across multiple capsids and payloads, PackGene is strengthening its position as a manufacturing partner for AAV-based gene therapy development, an increasingly important area of the biopharmaceutical industry. The ability to deliver scalable, high-quality viral vectors could help developers move promising gene therapy candidates more efficiently from preclinical research toward clinical development.
Source: PackGene Biotech press release
